Liquidia Corporation
LQDAHeld by 2 specialist biotech funds
2 funds opened new positions. Next phase2 readout (Inhaled dry powder treprostinil (LIQ861)): Dec 2020. Short interest: 13.9% of float.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.